https://www.selleckchem.com/pr....oducts/atuzabrutinib
To report toxicity of a hypofractionated scheme of whole-breast (W intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SI to the tumor bed (T using Tomotherapy with Direct modality. Patients with early breast cancer, undergoing radiotherapy (RT) in 15 daily fractions to WB (prescription dose 40.05Gy) and SIB to the TB (48Gy), between 2013 and 2017, was analyzed. Primary endpoint was acute and intermediate toxicity assessed at the end and within 6months from RT, according to Radiation Therapy Oncology
Curtir
Comentario
Compartilhar
